Australia markets close in 59 minutes
  • ALL ORDS

    6,847.80
    +75.80 (+1.12%)
     
  • ASX 200

    6,637.80
    +76.20 (+1.16%)
     
  • AUD/USD

    0.7317
    +0.0030 (+0.41%)
     
  • OIL

    43.45
    +0.39 (+0.91%)
     
  • GOLD

    1,822.20
    -15.60 (-0.85%)
     
  • BTC-AUD

    24,985.61
    -45.51 (-0.18%)
     
  • CMC Crypto 200

    366.84
    +5.41 (+1.50%)
     
  • AUD/EUR

    0.6175
    +0.0023 (+0.38%)
     
  • AUD/NZD

    1.0494
    -0.0032 (-0.30%)
     
  • NZX 50

    12,559.48
    +57.74 (+0.46%)
     
  • NASDAQ

    11,905.94
    -0.50 (-0.00%)
     
  • FTSE

    6,333.84
    -17.61 (-0.28%)
     
  • Dow Jones

    29,591.27
    +327.79 (+1.12%)
     
  • DAX

    13,126.97
    -10.28 (-0.08%)
     
  • Hang Seng

    26,494.90
    +8.70 (+0.03%)
     
  • NIKKEI 225

    26,253.61
    +726.24 (+2.84%)
     

Mediclinic International plc's (LON:MDC) Intrinsic Value Is Potentially 54% Above Its Share Price

Simply Wall St
·6-min read

How far off is Mediclinic International plc (LON:MDC) from its intrinsic value? Using the most recent financial data, we'll take a look at whether the stock is fairly priced by taking the forecast future cash flows of the company and discounting them back to today's value. We will take advantage of the Discounted Cash Flow (DCF) model for this purpose. Models like these may appear beyond the comprehension of a lay person, but they're fairly easy to follow.

We generally believe that a company's value is the present value of all of the cash it will generate in the future. However, a DCF is just one valuation metric among many, and it is not without flaws. If you want to learn more about discounted cash flow, the rationale behind this calculation can be read in detail in the Simply Wall St analysis model.

View our latest analysis for Mediclinic International

What's the estimated valuation?

We use what is known as a 2-stage model, which simply means we have two different periods of growth rates for the company's cash flows. Generally the first stage is higher growth, and the second stage is a lower growth phase. To start off with, we need to estimate the next ten years of cash flows. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.

Generally we assume that a dollar today is more valuable than a dollar in the future, so we need to discount the sum of these future cash flows to arrive at a present value estimate:

10-year free cash flow (FCF) forecast

2021

2022

2023

2024

2025

2026

2027

2028

2029

2030

Levered FCF (£, Millions)

UK£228.0m

UK£292.0m

UK£339.4m

UK£379.2m

UK£411.7m

UK£437.9m

UK£459.0m

UK£476.2m

UK£490.4m

UK£502.5m

Growth Rate Estimate Source

Analyst x1

Analyst x1

Est @ 16.23%

Est @ 11.73%

Est @ 8.57%

Est @ 6.37%

Est @ 4.82%

Est @ 3.74%

Est @ 2.99%

Est @ 2.46%

Present Value (£, Millions) Discounted @ 13%

UK£202

UK£228

UK£235

UK£232

UK£223

UK£210

UK£194

UK£178

UK£162

UK£147

("Est" = FCF growth rate estimated by Simply Wall St)
Present Value of 10-year Cash Flow (PVCF) = UK£2.0b

After calculating the present value of future cash flows in the initial 10-year period, we need to calculate the Terminal Value, which accounts for all future cash flows beyond the first stage. For a number of reasons a very conservative growth rate is used that cannot exceed that of a country's GDP growth. In this case we have used the 5-year average of the 10-year government bond yield (1.2%) to estimate future growth. In the same way as with the 10-year 'growth' period, we discount future cash flows to today's value, using a cost of equity of 13%.

Terminal Value (TV)= FCF2030 × (1 + g) ÷ (r – g) = UK£502m× (1 + 1.2%) ÷ (13%– 1.2%) = UK£4.3b

Present Value of Terminal Value (PVTV)= TV / (1 + r)10= UK£4.3b÷ ( 1 + 13%)10= UK£1.3b

The total value, or equity value, is then the sum of the present value of the future cash flows, which in this case is UK£3.3b. In the final step we divide the equity value by the number of shares outstanding. Relative to the current share price of UK£2.9, the company appears quite undervalued at a 35% discount to where the stock price trades currently. Remember though, that this is just an approximate valuation, and like any complex formula - garbage in, garbage out.

dcf
dcf

The assumptions

Now the most important inputs to a discounted cash flow are the discount rate, and of course, the actual cash flows. Part of investing is coming up with your own evaluation of a company's future performance, so try the calculation yourself and check your own assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Mediclinic International as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 13%, which is based on a levered beta of 1.119. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.

Moving On:

Whilst important, the DCF calculation is only one of many factors that you need to assess for a company. DCF models are not the be-all and end-all of investment valuation. Preferably you'd apply different cases and assumptions and see how they would impact the company's valuation. If a company grows at a different rate, or if its cost of equity or risk free rate changes sharply, the output can look very different. What is the reason for the share price sitting below the intrinsic value? For Mediclinic International, there are three relevant factors you should assess:

  1. Risks: Every company has them, and we've spotted 1 warning sign for Mediclinic International you should know about.

  2. Future Earnings: How does MDC's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.

  3. Other High Quality Alternatives: Do you like a good all-rounder? Explore our interactive list of high quality stocks to get an idea of what else is out there you may be missing!

PS. The Simply Wall St app conducts a discounted cash flow valuation for every stock on the LSE every day. If you want to find the calculation for other stocks just search here.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.